Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to
the confidential treatment request. Omissions are designated as * * *. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission.
AMENDMENT NO. 1 TO FEASIBILITY, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
This Amendment No. 1 to Feasibility, Development And Commercialization Agreement (“ Amendment No. 1 ”) is entered into
effective January 23, 2007 (the “ Amendment Date ”) by and between DURECT Corporation (“DURECT”) and Voyager
Pharmaceutical Corporation (“ Voyager ”).
A. Southern BioSystems, Inc., an Alabama corporation (“ SBS ”), and Voyager have previously entered into that certain
Feasibility, Development and Commercialization Agreement dated July 22, 2002 (the “ Agreement ”). Effective December 31,
2002, SBS merged with and into DURECT, with DURECT as the surviving corporation. As a result of such merger, DURECT
succeeded to all of the rights and obligations of SBS under the Agreement.
B. Voyager is currently engaged in collection and analysis of data from a clinical trial conducted for the Product prior to the
Amendment Date, namely Study VP-AD-301 (the “ Specified Clinical Trial ”), and desires financial and other assistance from
DURECT to complete such collection and analysis.
C. DURECT is willing to provide financial and other assistance to Voyager.
D. DURECT and Voyager desire to make certain amendments to the Agreement as set forth below.
THEREFORE, in consideration of the premises and mutual promises and covenants herein contained and for good and
valuable consideration, the sufficiency of which is hereby acknowledged, DURECT and Voyager hereby agree as follows:
1. Unless otherwise defined herein, all terms used herein shall have the same meaning ascribed to such terms in the
2. DURECT hereby permanently waives its right to receive payment from Vo